

PROGRESSIVE'S EVENING STROLL

DATE: 16 May, 2025

Market Snapshot:

After a muted start, the Index traded within a narrow range and eventually closed at 25,019.80 with a loss of 42.30 points. On the sectoral front, Realty and Media emerged as the top performers, while IT and Metal lagged. Despite the lacklustre movement in the Index, broader markets showed strong momentum, with Midcap and Smallcap segments gaining by 0.94% and 1.86% respectively, significantly outperforming the Benchmark Index.

HOW THE DAY TRENDED



INDICES

Index	Close	Points	%Chg.
Sensex	82330.59	(200.15)	(0.24)
Nifty50	25019.80	(42.30)	(0.17)
Nifty Midcap 100	57060.50	529.65	0.94
Nifty Small Cap 100	17560.40	320.45	1.86

SECTORAL GAINERS / LOSERS

Sectors	Close	Points	%Chg.
NIFTY REALTY	912.55	14.60	1.63
NIFTY MEDIA	1681.45	18.40	1.11
NIFTY ENERGY	35664.80	302.25	0.85
NIFTY IT	37972.35	(321.45)	(0.84)

NIFTY TOP GAINERS / LOSERS

Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
BEL	363.90	3.85	BHARTI AIRTEL	1814.00	(2.85)
BAJAJ AUTO	8482.50	1.88	HCL TECH	1659.90	(2.13)
TATA CONSUMER	1168.00	1.81	SBIN	792.10	(1.94)
ADANI ENT	2555.00	1.39	JSW STEEL	1021.80	(1.59)

INDICES LEVELS FOR May 19, 2025

Nifty (future)		Bank Nifty (future)	
Resistance	25280	Resistance	55900
Support	24850	Support	55000



PROGRESSIVE'S EVENING STROLL

DATE: 16 May, 2025

KEY TAKEAWAYS OF THE DAY

◆ **Remsons bags orders worth more than Rs3bn from Stellantis, North America for control cable:**

The company has secured an order of approx. Rs3bn (USD35mn) from Stellantis North America. This represents the single largest business win to date for the company. The company will supply critical components for iconic vehicle platforms such as the Jeep Wrangler and RAM, strengthening its position as a global automotive leader. It will also supply products for Smart car and 3-Wheeler into Stellantis Europe.

◆ **Marksans Pharma gets UK regulator nod for Gabapentin 50 mg/ml oral solution:**

The company announced its UK subsidiary Relonchem had secured marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) for its Gabapentin oral solution, 50 mg/ml. It is used for the treatment of nerve pain and epilepsy. Gabapentin is widely prescribed for the treatment of nerve pain and epilepsy, and the new oral solution format is particularly useful for patients who have difficulty swallowing tablets or capsules.

◆ **KalpataruProjs bags order worth Rs23.72bn for T&D, B&F businesses:**

The company has secured new orders/notification of awards of around Rs23.72bn. The company has received orders in the Power T&D business in India and the overseas market. The company has also received orders in the B&F business in India.

◆ **Infosys extends collaboration with DNB Bank to accelerate digital transformation:**

The company announced an expansion of its strategic collaboration with DNB Bank ASA (DNB), Norway's largest bank, to accelerate the bank's digital transformation. The collaboration will leverage Infosys' services, solutions, and platforms, including the Infosys Finacle platform to accelerate their IT modernization journey, improve resilience, and deliver enhanced customer experience. Through this collaboration Infosys will enhance DNB's IT resilience and customer service capabilities by applying its deep domain expertise and next-generation technologies.

◆ **RVNL received LOA from Central Railway for OHE modification in Itarsi-Amla section:**

The company has received a LoA from Central Railway for upgrading the electric traction system in Nagpur Division. The order includes OHE modification work for upgrading the existing 1x25KV electric traction system to 2x25KV at the feeding system in the Itarsi-Amla section in the Nagpur Division of Central Railway to meet the 3000MT loading target. The said order is worth Rs1150mn, and it will be executed within 24 months.

Source: Media Reports



DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai—400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Neha Oza,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500.

Grievance Officer:

Email: grievancecell@progressiveshares.com

